Item 9.01. Financial Statements and Exhibits. for Vanda

Send us Feedback

Vanda Pharmaceuticals (VNDA)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

VNDA » Topics » Item 9.01. Financial Statements and Exhibits.

This excerpt taken from the VNDA 8-K filed Feb 7, 2007.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated February 7, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.


	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: February 7, 2007

This excerpt taken from the VNDA 8-K filed Jan 22, 2007.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated January 22, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.


	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: January 22, 2007

This excerpt taken from the VNDA 8-K filed Dec 7, 2006.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated December 7, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.


	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: December 7, 2006

This excerpt taken from the VNDA 8-K filed Nov 15, 2006.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated November 15, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.


	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: November 15, 2006

This excerpt taken from the VNDA 8-K filed Nov 2, 2006.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated November 2, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.


	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: November 2, 2006

This excerpt taken from the VNDA 8-K filed Sep 12, 2006.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated September 12, 2006 regarding the resignation of Wayne T. Hockmeyer, Ph.D. from the Company’s Board of Directors.

99.2		Press release of Vanda Pharmaceuticals Inc. dated September 12, 2006 regarding the appointment of H. Thomas Watkins to the Company’s Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.


	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: September 12, 2006

This excerpt taken from the VNDA 8-K filed Aug 30, 2006.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated August 30, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.

	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: August 30, 2006

This excerpt taken from the VNDA 8-K filed May 18, 2006.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release of Vanda Pharmaceuticals Inc. dated May 18, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VANDA PHARMACEUTICALS INC.


	By:	/s/ STEVEN A. SHALLCROSS

	Name:	Steven A. Shallcross
	Title:	Senior Vice President, Chief Financial Officer and Treasurer

Dated: May 18, 2006

EXCERPTS ON THIS PAGE:

8-K	Feb 7, 2007

8-K	Jan 22, 2007

8-K	Dec 7, 2006

8-K	Nov 15, 2006

8-K	Nov 2, 2006

8-K	Sep 12, 2006

8-K	Aug 30, 2006

8-K	May 18, 2006

"Item 9.01. Financial Statements and Exhibits." elsewhere:

Affymax (AFFY)
Alnylam Pharmaceuticals (ALNY)
Anika Therapeutics (ANIK)
BioCryst Pharmaceuticals (BCRX)
Cadence Pharmaceuticals (CADX)
Cerus (CERS)
Clinical Data (CLDA)
Dyax (DYAX)
Enzon Pharmaceuticals (ENZN)
EPIX Pharmaceuticals (EPIX)
Exelixis (EXEL)
GTC Biotherapeutics (GTCB)
Halozyme Therapeutics (HALO)
Heska (HSKA)
Endo Pharmaceuticals Solutions Inc. (IDEV)
ImmunoGen (IMGN)
Iomai (IOMI)
InterMune (ITMN)
Metabasis Therapeutics (MBRX)
Medarex (MEDX)
Micromet (MITI)
Matritech (MZT)
Biota Pharmaceuticals, Inc. (NABI)
NGEN, INC. (NGEN)
Transcept Pharmaceuticals Inc (NOVC)
Neurobiological Technologies (NTII)
ARCA biopharma, Inc. (NUVO)
Omrix Biopharmaceuticals (OMRI)
Pharmacopeia Drug Discovery (PCOP)
Progenics Pharmaceuticals (PGNX)
Protalix BioTherapeutics (PLX)
Peregrine Pharmaceuticals (PPHM)
Repligen (RGEN)
Sangamo BioSciences (SGMO)
Savient Pharmaceuticals (SVNT)
Trubion Pharmaceuticals (TRBN)
Tercica (TRCA)
Targacept (TRGT)
SYNAGEVA BIOPHARMA CORP (TRMS)
XenoPort (XNPT)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

Vanda Pharmaceuticals (VNDA)

VNDA » Topics » Item 9.01. Financial Statements and Exhibits.

EXCERPTS ON THIS PAGE:

RELATED TOPICS for VNDA:

"Item 9.01. Financial Statements and Exhibits." elsewhere: